ArticleSleep & breathing = Schlaf & Atmung2026
Identification of shared biomarkers for obstructive sleep apnea and sarcopenia via differential expression and WGCNA analysis.
Article in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ashwin and FAM98 paralogs define nuclear and cytoplasmic RNA ligase complexes for tRNA biogenesis.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundObstructive sleep apnea (OSA) and sarcopenia are common age-related conditions that significantly reduce quality of life. OSA is characterized by recurrent breathing interruptions and chronic intermittent hypoxia, while sarcopenia involves progressive loss of muscle mass and strength. Accumulating evidence indicates that chronic intermittent hypoxia and sleep fragmentation in OSA may promote muscle wasting via inflammatory pathways (e.g., NF-κB), oxidative stress, and impaired protein synthesis. Conversely, sarcopenia-related muscle weakness may worsen upper airway collapsibility, creating a vicious cycle. However, the molecular mechanisms linking OSA and sarcopenia remain poorly understood.
methodsWe performed differential expression analysis on OSA and sarcopenia datasets from the Gene Expression Omnibus (GEO) and used weighted gene co-expression network analysis (WGCNA) to identify candidate biomarkers, with functional enrichment assessed under false discovery rate (FDR) correction. A diagnostic model was constructed based on key genes and validated using receiver operating characteristic (ROC), calibration, and decision curves. Immune cell infiltration was analyzed using the CIBERSORT algorithm.
resultsWe identified 123 differentially expressed genes shared by OSA and sarcopenia, enriched in pathways related to muscle function, cellular stress, metabolic disorders, and neurodegeneration. WGCNA identified ESF1, ZNF117, and C2orf49 as core genes. The diagnostic model showed high accuracy (area under the curve (AUC): 0.912 for OSA, and 0.967 for sarcopenia in training; 0.787 for OSA, and 0.744 for sarcopenia in validation). These genes were closely associated with pro-inflammatory immune cells.
conclusionThis study identifies ESF1, ZNF117, and C2orf49 as potential shared biomarkers for OSA and sarcopenia. The robust diagnostic model and the observed tissue-specific gene dysregulation illuminate the systemic interplay between these conditions, offering insights for risk stratification and future mechanistic research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.